Polyphenols Are Not Absorbed by You — They Are Transformed by Your Gut Bacteria Into Potent Metabolites, Which Means Your Response to Pomegranate, Soy, Red Wine, and Berries Depends Entirely on Which Microbes Live in Your Colon: the Science of Urolithins, Equol, and the Gut Biotransformation of Dietary Polyphenols
Updated: June 2026 · polyphenols gut · polyphenols microbiome · gut polyphenols · polyphenol metabolism gut bacteria · polyphenol biotransformation · gut bacteria polyphenols · microbiome polyphenols · polyphenol bioavailability · polyphenol absorption · why polyphenols don't absorb · polyphenol gut metabolism · urolithin · urolithin A · urolithin A supplement · urolithin A benefits · urolithin A mitophagy · urolithin A muscle · urolithin A aging · urolithin A gut · pomegranate urolithin · pomegranate ellagitannins · ellagitannins gut bacteria · ellagic acid urolithin · Amazentis urolithin · Timeline urolithin · ATLAS trial urolithin · urolithin A clinical trial · urolithin A RCT · Liu 2022 Nature Aging · Liu urolithin A · urolithin A mitochondria · urolithin A autophagy · urolithin muscle strength · urolithin A 500mg · how to produce urolithins · urolithin producer · urolithin non-producer · equol · equol soy · equol isoflavones · equol producer · equol non-producer · soy isoflavones gut · daidzein equol · Slackia isoflavoniconvertens · equol and menopause · equol bone density · equol cancer · equol breast cancer · equol hot flashes · equol benefits · equol gut bacteria · how to produce equol · equol producer test · soy isoflavones benefits men · soy isoflavones benefits women · soy menopause · genistein daidzein · resveratrol gut · resveratrol microbiome · resveratrol bioavailability · resveratrol absorption · resveratrol metabolites · resveratrol dihydroresveratrol · pterostilbene vs resveratrol · pterostilbene bioavailability · pterostilbene gut · anthocyanin gut · anthocyanin metabolism · anthocyanin microbiome · berry polyphenols gut · blueberry microbiome · quercetin gut · quercetin absorption · quercetin glucoside · quercetin aglycone · quercetin isorhamnetin · polyphenol gut diversity · gut diversity polyphenols · prebiotics polyphenols · polyphenol prebiotic effect · polyphenol gut bacteria growth · polyphenol Akkermansia · polyphenol Bifidobacterium · polyphenol Lactobacillus
Dietary polyphenols — the vast category of plant compounds including flavonoids, phenolic acids, stilbenes, lignans, and tannins — are frequently described as powerful antioxidants and health-promoting compounds. What textbooks and supplement labels rarely convey is that most polyphenols are not absorbed intact. Polyphenol molecules are often large, poorly soluble, and chemically fragile. The small intestine absorbs only a small fraction; the majority (typically 90–95%) reaches the colon intact, where they are extensively metabolized by the gut microbiome into a diverse array of phenolic metabolites — many of which are more bioactive, more bioavailable, and more tissue-penetrant than the parent compound.
This creates a profound problem: clinical trials studying polyphenols typically measure compound X (resveratrol, quercetin, ellagic acid) and find variable results — some participants respond strongly, others show no effect. The variability is not a flaw in the study design or a sign that the compound doesn't work. It reflects microbial variability between participants: individuals who harbor the bacterial enzymes required to produce the bioactive metabolite respond; those who lack those bacteria — sometimes the majority of participants — do not. Urolithins from pomegranate and equol from soy are the best-documented examples, but the principle applies across the polyphenol landscape.
Urolithins (ATLAS Trial)
the best-studied polyphenol metabolite story: PARENT COMPOUNDS: ellagitannins — large, complex tannin polymers found in pomegranate (punicalagins), walnuts (pedunculagin), strawberries, raspberries, oak-aged wines, and other foods; ellagitannins are hydrolyzed in the gut to ellagic acid → ellagic acid is then sequentially metabolized by Gordonibacter pamelaeae, Gordonibacter urolithinfaciens, and Ellagibacter isourolithinifaciens (recently characterized in 2019–2021) into: urolithin M5 → urolithin M6 → urolithin M7 → urolithin C → urolithin A (the most bioactive, furthest downstream); WHO CONVERTS: only approximately 40% of Western adults produce meaningful urolithin A (urolithin A producers); approximately 30% produce mainly upstream intermediates (urolithin M6, C — "metabotype B" — partial producers); approximately 30% produce negligible urolithins ("metabotype 0" — non-producers); metabotype is relatively stable and related to microbiome composition — specifically, the presence of Gordonibacter and Ellagibacter species; UROLITHIN A MECHANISM: urolithin A activates PINK1/Parkin-mediated mitophagy — the cellular pathway that clears damaged mitochondria (quality control); it upregulates mitochondrial biogenesis markers (PGC-1α, NRF2); reduces mitochondrial reactive oxygen species; in animal models, urolithin A extends lifespan in C. elegans and improves muscle function in aged mice; ATLAS TRIAL (Liu et al., 2022, Nature Aging): the first Phase II RCT of urolithin A supplementation in older adults (ages 65–90); N=66; design: 4 months, 3 arms (500mg UA, 1,000mg UA, placebo); PRIMARY OUTCOME: skeletal muscle mitophagy biomarkers (LC3A/B flux, sequestosome-1/p62) in muscle biopsy; RESULTS: 500mg UA group: +12% increase in mitophagy-related gene expression panel in muscle biopsy vs placebo; significant improvement in 6-minute walk distance; trend toward improved hand grip (did not reach significance); 1,000mg group: comparable but not superior to 500mg; TOLERABILITY: excellent; no serious adverse events; SIGNIFICANCE: this is proof-of-concept that supplemental UA bypasses the microbiome conversion limitation; non-producers become responders when given pre-formed UA; Amazentis (now Timeline Nutrition) markets urolithin A as "Mitopure" at 500mg/day
Equol (30–50% Produce It)
the soy isoflavone biotransformation lottery: PARENT COMPOUNDS: soy isoflavones — daidzein and genistein are the primary soy isoflavones; consumed as glycoside forms (daidzin, genistin) → intestinal glucosidases cleave the glycoside → release daidzein and genistein aglycones → some is absorbed directly in the small intestine; in the colon, daidzein is further metabolized to: equol (a more potent phytoestrogen with 10× higher estrogen receptor affinity than daidzein) OR O-desmethylangolensin (O-DMA, less potent); EQUOL PRODUCTION: requires gut bacteria — specifically Slackia isoflavoniconvertens, Adlercreutzia equolifaciens, and Lactococcus garvieae strains; PREVALENCE: approximately 25–30% of adults in Western populations are equol producers; 50–60% of adults in Asian populations (Japan, Korea, China) are equol producers — attributed to dietary soy history shaping microbiome composition over generations; equol producer status is partially modifiable: consuming soy regularly for 4+ weeks increases equol producer prevalence; probiotics containing Lactobacillus and Bifidobacterium strains (if they carry the required reductase genes) may help; CLINICAL IMPLICATIONS OF EQUOL PRODUCER STATUS: WHY IT MATTERS — virtually all the clinical benefit attributed to soy isoflavones in menopause (hot flash reduction), bone density preservation, and some cancer risk reduction may be conferred disproportionately or entirely by equol; meta-analyses of soy/isoflavone RCTs consistently show higher effect sizes in Asian cohorts (more equol producers) vs Western cohorts; EQUOL FOR MENOPAUSE: Howes LG et al. (multiple meta-analyses): equol producer women show significant reduction in vasomotor symptoms (hot flashes, night sweats) from soy; non-producers show minimal benefit; EQUOL AND BONE: Atkinson C et al. (2004, AJCN): in postmenopausal women, only equol producers showed significant bone mineral density preservation with isoflavone supplementation; CLINICAL TEST: equol producer testing is not widely available clinically; some research labs measure urinary equol/daidzein ratio; indirect proxy: regular soy consumers with Japanese or Korean ancestry are more likely producers; SUPPLEMENT NOTE: S-equol (the active enantiomer) is available as a direct supplement — bypasses the microbial conversion step, similar to urolithin A supplementation; approved in Japan; increasingly available in the US
Resveratrol Paradox
why the SIRT1 activator underdelivers in trials: PARENT COMPOUND: resveratrol (3,4',5-trihydroxystilbene) — found primarily in red wine, grape skins, Japanese knotweed (Polygonum cuspidatum), and some berries; concentration in red wine: 1–12 mg/L (a glass of red wine contains ~0.5–2mg resveratrol — far below the 150–1,000mg doses used in most human trials); BIOAVAILABILITY PROBLEM: oral resveratrol is almost completely absorbed in the small intestine (~75% of a dose) — this seems good; HOWEVER: it undergoes extensive first-pass phase II metabolism (sulfation and glucuronidation) immediately in the intestinal epithelium and liver → circulating resveratrol is predominantly resveratrol-3-sulfate and resveratrol-3-glucuronide (conjugated forms) → these conjugates have 10–50× lower biological activity than free resveratrol at the target sites (SIRT1, AMP kinase); SERUM LEVELS: even after a 500mg oral dose, free (unconjugated) resveratrol serum levels are typically <10 ng/mL — far below concentrations shown to activate SIRT1 in vitro; COLONIC METABOLISM: unabsorbed resveratrol (a small fraction) reaches the colon → reduced to dihydroresveratrol, lunularin, and other metabolites by gut bacteria — some of which may have activity but are poorly characterized; CLINICAL RESULTS: CALERIE, MOST, and other resveratrol RCTs in humans have largely failed to replicate the dramatic lifespan/SIRT1 benefits seen in yeast and mice; WHY: species differences in resveratrol pharmacokinetics; conjugation chemistry differs between humans and rodents; PTEROSTILBENE ADVANTAGE: pterostilbene (a resveratrol analog from blueberries) has two methyl groups instead of hydroxyl groups → methyl groups block phase II conjugation → pterostilbene's oral bioavailability (~80%) and free plasma concentration is ~10× higher than resveratrol; PTEROSTILBENE RCTs: modest benefits on lipids and glucose in early human trials; not yet well-studied for longevity endpoints; GUT MICROBIOME ANGLE: resveratrol at higher doses appears to modestly increase Lactobacillus and Bifidobacterium and decrease Clostridiales in some studies — potential prebiotic-like effect independent of SIRT1
Quercetin & Anthocyanins
absorption, transformation, and the microbiome: QUERCETIN FORMS: quercetin aglycone (pure quercetin, poorly absorbed — 25% oral bioavailability) vs quercetin glucoside (quercetin-4'-O-glucoside, found in onions; absorbed by SGLT1 and lactase-phlorizin hydrolase in the small intestine → 52% bioavailability) vs quercetin rutinoside (rutin, found in buckwheat and tea; poorly absorbed → reaches colon → cleaved to quercetin aglycone by gut bacterial rhamnosidases); QUERCETIN COLONIC METABOLISM: gut bacteria convert quercetin to 3,4-dihydroxyphenylacetic acid, 3-hydroxyphenylacetic acid, and phenylpropionic acids — metabolites with anti-inflammatory and antioxidant activity that may contribute to benefits attributed to quercetin; QUERCETIN BIOAVAILABILITY TIP: consume with fat (quercetin's lipophilicity means fat improves micellar incorporation and absorption); quercetin-3-O-glucoside forms (onion quercetin) are superior to aglycone or rutinoside supplements; ANTHOCYANINS: the blue-red-purple pigments in berries, red cabbage, purple grapes; consumed as glycosides; exhibit very low intact absorption (roughly 1–5% absorbed in small intestine); the remaining 95%+ is extensively transformed in the colon to phenolic acids (protocatechuic acid, vanillic acid, syringic acid, ferulic acid); GUT MICROBIOME EFFECTS OF ANTHOCYANINS: blueberry anthocyanins increase Bifidobacterium, Lactobacillus, and Akkermansia muciniphila in human feeding studies; the fiber in blueberries is fermented to SCFA; the combination of polyphenol-driven Akkermansia growth + SCFA production likely underlies much of berries' metabolic benefit; TOTAL POLYPHENOL INTAKE: diverse polyphenol consumption (multiple colors, multiple food sources) supports more diverse gut bacterial enzyme capacity for biotransformation → each color/class feeds slightly different bacterial groups → polyphenol diversity → microbial diversity (true in both directions); PRACTICAL IMPLICATION: consuming whole fruits and vegetables provides the polyphenol matrix (multiple compounds) + fiber (fermentation substrate) + co-factors for biotransformation — supplement forms (isolated quercetin, resveratrol) remove the matrix and may underperform vs whole-food sources
Ready to fix this at the root?
The 30-Day Gut Reset is the full day-by-day protocol — mechanisms, dosed repair steps, a diagnostic chapter, food/swap tables, and a maintenance plan, built from the same research on this page.
Get the Gut Reset → $19
Polyphenol Biotransformation by Gut Bacteria
| Parent Polyphenol | Gut Bacterial Metabolites | Key Bacteria Required | % Population Efficient Converters | Bioactive Endpoint |
|---|
| Ellagitannins (pomegranate, walnuts) | Urolithin A, B, C, M5-M7 | Gordonibacter urolithinfaciens, Ellagibacter isourolithinifaciens | ~40% (metabotype A) | Mitophagy activation, muscle function |
| Daidzein (soy) | S-equol, O-DMA | Slackia isoflavoniconvertens, Adlercreutzia equolifaciens | ~30% West / ~50% East Asia | ERβ agonism, menopause, bone density |
| Resveratrol (grapes, knotweed) | Dihydroresveratrol, lunularin, 3,4'-DHR | Various colonic bacteria; also small intestine sulfation (limits free resveratrol) | ~100% (conversion happens; efficacy debated) | Antioxidant; SIRT1 activation limited by conjugation |
| Quercetin rutinoside (rutin) (buckwheat, tea) | Quercetin aglycone → phenolic acids | Ruminococcus, Bacteroides (α-rhamnosidases) | ~70% | Anti-inflammatory phenolic acids |
| Anthocyanins (berries, red cabbage) | Protocatechuic acid, vanillic acid, ferulic acid | Diverse colonic bacteria; strains with glycoside hydrolases | ~80% | Antioxidant; Akkermansia growth stimulation |
| Lignans (flaxseed, sesame) | Enterolactone, enterodiol | Blautia producta, Lactonifactor longoviformis | ~50% efficient | Weak phytoestrogen; breast cancer risk reduction in some cohorts |
Maximizing Polyphenol Biotransformation — Diet and Supplement Strategy
Food strategy for producers: POMEGRANATE / UROLITHINS: if you are an established urolithin A producer (older dietary history of pomegranate, walnuts), 240mL pomegranate juice daily provides ~300–500mg punicalagins → gut bacteria convert to ~50–100mg urolithin A equivalent in systemic circulation; supplements with pre-formed urolithin A (Mitopure 500mg) bypass the conversion step entirely and are appropriate for non-producers or for consistent delivery; for non-producers, pomegranate juice provides minimal urolithin A but still delivers Akkermansia-feeding polyphenols and fiber; SOY / EQUOL: for menopausal women targeting equol benefits, 25–50g of whole soy foods daily (edamame, tofu, tempeh — not soy isolate protein, which removes most isoflavones) provides 30–60mg isoflavones; consume for at least 6–8 weeks before assessing response; equol producer status may increase with regular soy consumption; fermented soy foods (tempeh, natto, miso) provide both isoflavones and live bacteria that may include equol-producing strains; if hot flash response after 8 weeks is minimal, consider direct S-equol supplement (40–80mg/day); BERRIES / ANTHOCYANINS: 1 cup (150g) mixed berries provides ~200–300mg anthocyanins; eat with oat fiber (β-glucan) → the fiber feeds Akkermansia alongside the anthocyanin → synergistic effect on gut diversity and tight junction maintenance; blueberries + flaxseed is a particularly well-studied combination (anthocyanins + lignans → Akkermansia + enterolactone); RESVERATROL / PTEROSTILBENE: whole red grapes and red wine provide resveratrol at doses too low for SIRT1 activation but sufficient for prebiotic effects on Lactobacillus/Bifidobacterium; if targeting higher doses, pterostilbene 50–150mg/day has superior bioavailability over resveratrol and modest RCT evidence for lipid and glucose effects; resveratrol supplements at 150–250mg/day may be worthwhile as a prebiotic booster (gut benefit) even if SIRT1 activation is limited.
Supplement selection: UROLITHIN A: 500mg/day (Mitopure is the only RCT-validated form — the ATLAS trial data was conducted with Amazentis Mitopure; generic urolithin A products may be equivalent but lack clinical trial data); take in the morning; no interactions with standard supplements; S-EQUOL: if pursuing equol non-producer route, 10–40mg S-equol daily; primarily for menopausal women (hot flash reduction, bone density support); men: soy phytoestrogen concerns at very high intakes are largely theoretical in normal food amounts; therapeutic equol doses used in Japanese clinical trials are 10mg TID; QUERCETIN: for supplementation, quercetin glucoside or quercetin phytosome (EMIQ or Quercefit form) is absorbed significantly better than standard quercetin aglycone; 500mg/day standard quercetin has modest antihistamine, anti-inflammatory, and senolytic-adjunct activity; GUT DIVERSITY CORNERSTONE: the master key to optimal polyphenol biotransformation is gut microbial diversity — a high-fiber (30g+/day, multiple fiber types), high-plant-variety diet creates the ecological conditions for Gordonibacter, Slackia, Adlercreutzia, Blautia, Lactonifactor and other specialized polyphenol-converting bacteria to establish and persist.
Urolithin A 500mg →
Pomegranate Ellagitannin Extract →
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.